In animal models, a new forward-oriented lentiviral vector outperforms the reverse-oriented vectors ordinarily used to deliver gene therapies for sickle-cell disease. The new vectors, which retain the sensitive intron 2 element, can increase vector titers sixfold and increase transduction efficiency four- to tenfold.
At the SynBioBeta 2019 conference in San Francisco, Inscripta launched the Onyx—a fully automated benchtop instrument for genome-scale engineering. The CRISPR-mediated, massively parallel platform—which includes software, consumables, instrument, and assays enables researchers to engineer microbial libraries containing the full breadth and scope of possible edit types, in their own labs.
Every inquisitive diagnostician looking to uncover infectious disease or cancer will want to give CRISPR-based tests a close look. Their paper strips and smartphone apps can deliver the inside skinny.
Genomic medicine is borrowing from Greek theatre a device called God in the Machine. In genomic medicine, the device manifests as AI technology, but it can still resolve complicated situations.
To reach the clinical big time, gene therapy producers need to get their act together, improving transfection, ensuring consistency, enhancing purity and increasing yields.
Sponsored content brought to you by In the gene and cell therapy field, there is a clear need to have cost-effective, scalable processes in the...
There is high demand for a method that can rapidly and directly measure AAV particle concentration. With the development of Multi-Angle Dynamic Light Scattering (MADLS?), the Zetasizer Ultra from Malvern Panalytical provides both rapid, accurate viral titer measurements and aggregation profiles in minutes.
Cas9 from Streptococcus pyogenes (SpCas9) is a precise nuclease, but it can be too large for the payload-limited AAV vector commonly used to deliver gene editing components into cells. The wild-type Cas9 from Staphylococcus aureus (SaCas9) easily fits inside the AAV, but it lacks SpCas9’s precision. Fortunately, rationally engineered SaCas9 variants have been shown to have high genome-wide specificity.
Beam Therapeutics has disclosed plans to go public, submitting plans for an initial public offering (IPO) that would raise up to $100 million for the year-old company founded by gene editing pioneers to develop new treatments based on base editing.
A genetic program adapted from bacteria for mammalian cells enables the expression acoustic reporter genes. These genes encode proteins that contribute to the assembly of proteinaceous gas vesicles, which may serve as ultrasound contrast agents. This novel live-cell imaging technology could allow gene expression to be monitored in the deep tissues of living animals.
Please wait while you are redirected to the right page...